PolyPeptide Group AG Sustainability Reports
PolyPeptide Group AG operates as a specialized contract development and manufacturing organization (CDMO) focused on peptide-based active pharmaceutical ingredients. The company serves pharmaceutical and biotechnology firms, providing therapeutic peptides from pre-clinical research through to commercial-scale manufacturing.
Sector: Manufacturing
Country: Switzerland
Exchange: SIX Swiss Exchange
LEI: 5067007JCKTPOX4G9758
FIGI: BBG0100P02X1
5 reports from 2021 to 2025
